Skip to main content

Iconix Receives NCI SBIR Grant to Develop In Vitro Liver Toxicity Assays

NEW YORK, Dec. 21 (GenomeWeb News) - Iconix Pharmaceuticals has won a Phase I SBIR grant from the National Cancer Institute to develop new cell-based methods for testing drug candidates for liver toxicity, the company said today.

 

The grant will allow the Mountain View, Calif.-based company to apply its chemogenomics technology to high-volume testing of drug candidates and environmental chemicals for their potential long-term effects on the liver. Iconix plans to develop in vitro patterns of genomic change that can be used as biomarkers of liver toxicity.

 

The amount of the grant was not immediately available from the company. The NIH database lists one six-month, $97,654 award for Iconix from the NCI this year entitled "Development of In Vitro Toxicity Expression Assays."

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.